Kazia Therapeutics
KZIA
6 hedge funds and large institutions have $92K invested in Kazia Therapeutics in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
14% less funds holding
Funds holding: 7 → 6 (-1)
28% less capital invested
Capital invested by funds: $127K → $92K (-$35K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$53.7K |
| 2 |
Morgan Stanley
New York
|
+$5.11K |
| 3 |
PP
Palladium Partners
Norfolk,
Virginia
|
+$852 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$62K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$11.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$11.1K |
| 4 |
BWFA
Baltimore-Washington Financial Advisors
Columbia,
Maryland
|
-$5K |
| 5 |
Citigroup
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $52K | +$53.7K | +63 | New |
|
|
2
Morgan Stanley
New York
| $17K | +$5.11K | +6 | +40% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $16K | -$11.1K | -13 | -39% |
|
|
U
4
UBS
Zurich,
Switzerland
| $5K | -$11.9K | -14 | -70% |
|
5
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
PP
6
Palladium Partners
Norfolk,
Virginia
| $1K | +$852 | +1 | New |
|
|
VKH
7
Virtu KCG Holdings
New York
| – | -$62K | -73 | Closed |
|
|
BWFA
8
Baltimore-Washington Financial Advisors
Columbia,
Maryland
| – | -$5K | -6 | Closed |
|
|
9
Citigroup
New York
| – | -$1K | -2 | Closed |
|
KZIA Hedge Fund Activity: Q1 2014 in Review
6 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2014, worth a combined $92K — down 28% from $127K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of KZIA and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $53.7K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $62K sold.
- 6 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2014, down from 7 in Q4 2013.
- Funds reported $92K of Kazia Therapeutics stock for Q1 2014, down 28% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q1 2014 and 3 closed out, a net change of -1 holder.
- The largest Kazia Therapeutics buyer in Q1 2014 was Citadel Advisors, an estimated $53.7K added.
- The largest Kazia Therapeutics seller in Q1 2014 was Virtu KCG Holdings, an estimated $62K sold.
Based on aggregated 13F filings for Q1 2014.